Fed. Circ. Won't Rehear Amgen Drug Patent Fight
The Federal Circuit said Friday that it won't revisit a decision that dashed Indian drugmaker Cipla Ltd.'s efforts to break Amgen's grip on its anti-cancer drug Kyprolis....To view the full article, register now.
Already a subscriber? Click here to view full article